VNRX - VolitionRx Limited

NYSE American - NYSE American Delayed Price. Currency in USD
5.16
-0.16 (-3.01%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.32
Open5.46
Bid5.20 x 800
Ask5.67 x 1000
Day's Range5.12 - 5.56
52 Week Range1.67 - 6.84
Volume251,843
Avg. Volume242,248
Market Cap212.024M
Beta (3Y Monthly)3.00
PE Ratio (TTM)N/A
EPS (TTM)-0.48
Earnings DateNov 5, 2019 - Nov 11, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.67
Trade prices are not sourced from all markets
  • PR Newswire

    Volition Appoints Dr. Phillip Barnes to Board of Directors

    AUSTIN, Texas, Oct. 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the appointment of Dr. Phillip Barnes to the Company's Board of Directors as a Non-Executive Director, effective October 9, 2019. Dr. Barnes was also appointed to the Company's Audit, Compensation and Nominations and Governance Committees. As a non-executive member of the Company's Board, Dr. Barnes will provide independent expertise and strategic counsel to VolitionRx in connection with the planned commercialization of its Nu.QTM blood-based diagnostic platform.

  • Do Institutions Own VolitionRx Limited (NYSEMKT:VNRX) Shares?
    Simply Wall St.

    Do Institutions Own VolitionRx Limited (NYSEMKT:VNRX) Shares?

    A look at the shareholders of VolitionRx Limited (NYSEMKT:VNRX) can tell us which group is most powerful. Generally...

  • PR Newswire

    Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes

    AUSTIN, Texas, Sept. 17, 2019 /PRNewswire/ --  VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced a significant milestone in its Nu.QTM Capture development program: the ability to enrich nucleosomes, and therefore, DNA of tumor versus non-tumor origin. This breakthrough could be used in two ways, firstly to increase specificity in Volition's current assays by removing the background signal and secondly, as an enabling technology in sequencing-based liquid biopsies by enriching nucleosomes of cancer origin from the blood. Dr. Mark Eccleston, one of the founding Scientists and the Business Development Director at Volition commented, "I am extremely excited that this enabling technology could bridge the gap between Volition's epigenetic profiling approach to early detection and those sequencing approaches that have so far been limited to personalized treatment selection.

  • ACCESSWIRE

    VolitionRX Ltd. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 13, 2019 / VolitionRX Ltd. (NYSE: VNRX ) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on August 13, 2019 at 8:30 AM Eastern ...

  • PR Newswire

    VolitionRx Limited Announces Second Quarter 2019 Financial Results and Business Update

    AUSTIN, Texas, Aug. 12, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the second quarter ended June 30, 2019. Volition management will host a conference call tomorrow, August 13, at 8:30 a.m. U.S. Eastern Time to discuss these results. Click here to view an interview with Volition's Chief Executive Officer.

  • PR Newswire

    Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer

    AUSTIN, Texas, Aug. 8, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced the recent formation of a subsidiary, Volition Veterinary Diagnostics Development LLC ("Volition Veterinary"), and the appointment of animal health expert Nathan Dewsbury as its Chief Executive Officer.  A video regarding this announcement can be viewed here. "It was important to form a U.S. based Volition Veterinary subsidiary to enable dedicated focus on the development and commercialization of our Nu.QTM Vet products and help drive product development and early revenue for the company," commented Cameron Reynolds, President and Chief Executive Officer of Volition. Mr. Dewsbury has global expertise in the animal health industry having direct involvement in national testing programs, current health diagnostics platforms and commercializing next generation diagnostics.

  • PR Newswire

    VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call and Business Update

    Conference call to take place Tuesday, August 13, 2019 at 8:30 am Eastern time AUSTIN, Texas , Aug. 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) today announced it will host a conference ...

  • PR Newswire

    Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock

    Volition intends to use the net proceeds from this warrant exercise for continued product development, clinical studies, product commercialization, working capital, and other general corporate purposes. The shares of common stock issued upon exercise of the warrant were offered to an accredited investor in reliance on an exemption from the registration requirements of the Securities Act of 1933, as amended (the "Securities Act"), and the rules and regulations promulgated thereunder.

  • PR Newswire

    VolitionRx Limited Commences Lung Cancer Clinical Study with Fosun Long March in China

    AUSTIN, Texas, July 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a contract under the previously announced Memorandum of Understanding, with Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March") to help introduce the Nu.Q(TM) platform to China. Based on recent promising proof-of-concept data using Volition's product-grade Nu.Q assays, the parties have commenced a clinical study in China in lung cancer.

  • PR Newswire

    VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding

    AUSTIN, Texas, July 10, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has been awarded additional non-dilutive funding in the form of a non-repayable cash grant totaling approximately $1.4 million from the Walloon Region, Belgium.  To date, Agencies from the Region have awarded Volition an aggregate of approximately $6 million in non-dilutive funding including this most recent award. "It is a key part of our financing strategy to actively seek non-dilutive funding as this provides additional cash at favourable terms to support the Company's continued development," commented Cameron Reynolds, President and Chief Executive Officer of Volition. Dr. Gaetan Michel, Chief Executive Officer of Volition's subsidiary, Belgian Volition SPRL, commented "We are delighted with the financial assistance that we have received from the Walloon Region and would like to thank Monsieur Pierre-Yves Jeholet, the Walloon Minister for Economy for his continued support.

  • Did You Miss VolitionRx's (NYSEMKT:VNRX) Impressive 116% Share Price Gain?
    Simply Wall St.

    Did You Miss VolitionRx's (NYSEMKT:VNRX) Impressive 116% Share Price Gain?

    The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...

  • Zacks Small Cap Research

    VNRX: 2019 Could Be Busy Year of Data Releases, Assay Validations

    On May 9th VolitionRx (VNRX) reported financial results for their fiscal 2019 first quarter ending March 31st. The study will include 1,200 participants receiving low-dose CT scan, 1,000 of which have lung cancer.

  • Associated Press

    VolitionRX: 1Q Earnings Snapshot

    On a per-share basis, the Singapore-based company said it had a loss of 12 cents. In the final minutes of trading on Wednesday, the company's shares hit $3.36. A year ago, they were trading at $2.41. _____ ...

  • PR Newswire

    VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update

    AUSTIN, Texas, May 8, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced financial results and a business update for the first quarter ended March 31, 2019. Volition management will host a conference call tomorrow, May 9, at 8:30 a.m. U.S. Eastern Time to discuss these results. Mr. Reynolds further commented "We were very happy to report the initial data from the first of our product grade assays during this first quarter.

  • PR Newswire

    VolitionRx Limited Executes a Contract for Clinical Trial Program in Lung Cancer

    AUSTIN, Texas, May 7, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of a contract under the previously announced Memorandum of Understanding, to conduct its first large-scale lung cancer study in conjunction with the prestigious National Taiwan University ("NTU"). The study will be conducted under the supervision of Professor Chen Jin-Shing in the Department of Surgery of NTU and will include 1,200 subjects receiving Low-Dose Computed Tomography scans, including 1,000 with lung cancer. Professor Chen Jin-Shing commented: "Lung cancer remains the deadliest of all the cancers and there is a high unmet clinical need for either a non-invasive early stage lung cancer detection test or for a triage test which can improve the specificity of the Low-Dose CT scan currently used.

  • PR Newswire

    VolitionRx Limited Schedules First Quarter 2019 Earnings Conference Call and Business Update

    Conference call to take place Thursday, May 9, 2019 at 8:30 am Eastern time AUSTIN, Texas , May  6 , 2019 /PRNewswire/ -- VolitionRx Limited (NYSE American:  VNRX) today announced it will host a conference ...

  • Zacks Small Cap Research

    VNRX: Entry Into China, Taiwan Large Lung Cancer Study and Animal Diagnostics Subsidiary

    Following reporting of Q4 earnings in mid-March, VolitionRx (VNRX) had a spate of news leading up to their ‘Capital Markets Day on April 9th at the New York Stock Exchange. The news is an extension of the product development related updates provided during the Q4 earnings call, which as a reminder, included new (i.e.

  • Loss-Making VolitionRx Limited (NYSEMKT:VNRX) Expected To Breakeven
    Simply Wall St.

    Loss-Making VolitionRx Limited (NYSEMKT:VNRX) Expected To Breakeven

    VolitionRx Limited's (NYSEMKT:VNRX): VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. On 31 December 2018, the US$128m market-cap pos...

  • PR Newswire

    VolitionRx Limited Hosts Capital Markets Day at the New York Stock Exchange and Issues Company Update Report

    ISNES, Belgium, April 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") hosted a Capital Markets Day at the New York Stock Exchange today to update interested parties on its recent progress. "It has been a busy quarter with the public announcement of a number of initiatives and we were delighted to have the opportunity to discuss our plans at the Capital Markets Day event today," commented Chief Executive Officer, Cameron Reynolds. Following recently announced preliminary results from two proof of concept studies in lung cancer, Volition has signed a Memorandum of Understanding with the prestigious National Taiwan University through its wholly-owned subsidiary, Belgian Volition SPRL ("Belgian Volition"), to conduct a large-scale lung cancer study.

  • PR Newswire

    VolitionRx Limited Signs Memorandum of Understanding with Texas A&M University for Potential Collaboration to Develop Nu.QTM Veterinary Diagnostics

    ISNES, Belgium, April 9, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") through its wholly-owned subsidiary, Belgian Volition SPRL, with Texas A&M University, a member of The Texas A&M University System. Pursuant to the terms of the MOU, the parties will explore the feasibility of a collaborative research relationship.  Any such relationship is subject to the negotiation of terms and conditions and the entry into a final binding agreement.  The MOU contemplates that Belgian Volition would form a new subsidiary in the United States to focus on the veterinary diagnostic market utilizing its NucleosomicsTM technology ("Vetco") and Texas A&M University would collaborate on the research and development of veterinary diagnostic products and is interested in negotiating a shareholding in Vetco.

  • PR Newswire

    VolitionRx Limited Extends Clinical Trial Program in Lung Cancer

    ISNES, Belgium, April 3, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that it has added to its extensive clinical trial program with the execution of a non-binding Memorandum of Understanding, through its wholly-owned subsidiary, Belgian Volition SPRL, to conduct its first large-scale lung cancer study in conjunction with the prestigious National Taiwan University ("NTU"). The study will be conducted under the supervision of Professor Chen Jin-Shing in the Department of Surgery of NTU and will include 1,200 subjects receiving Low-Dose Computed Tomography scans, including 1,000 with lung cancer. Professor Chen Jin-Shing commented: "The early data of the Nu.QTM technology platform is promising but clearly larger scale studies are required. Lung cancer remains the deadliest of all the cancers and there is a high unmet clinical need for either a non-invasive early stage lung cancer detection test or for a triage test which can improve the specificity of the Low-Dose CT scan currently used.

  • PR Newswire

    VolitionRx Limited Signs Memorandum of Understanding with Fosun Long March in China

    ISNES, Belgium, March 28, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") has executed a nonbinding Memorandum of Understanding ("MOU") with Shanghai Fosun Long March Medical Science Co., Ltd. ("Fosun Long March") with an expectation of negotiating and entering into a binding agreement to help facilitate the entrance of the Nu.QTM platform into China. Based on recent promising proof-of-concept data using Volition's product-grade Nu.Q assays, particularly in lung cancer, subject to reaching agreement on the terms and conditions of the proposed relationship, the parties intend to conduct three clinical studies in China in colorectal cancer, lung cancer and ovarian cancer.

  • PR Newswire

    VolitionRx Limited to Present at Conferences in March & April 2019

    ISNES, Belgium , March 25, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Executive Vice President, Investor Relations, Scott Powell , is ...

  • Zacks Small Cap Research

    VNRX: Initial Product Grade Assay Data is Compelling. Strategy Update On April 9th

    VolitionRx (VNRX) reported Q4 financial results and provided a business update. Timelines have been regularly delayed as the clinical grade assays work their way through the ‘product grade’ validation processes and studies.